Ada Girnita Selected Research

picropodophyllin

1/2010	Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma.
11/2008	Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.
11/2008	The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
6/2008	Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.
2/2006	The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ada Girnita Research Topics

Disease

19	Neoplasms (Cancer) 01/2022 - 07/2003
7	Melanoma (Melanoma, Malignant) 01/2022 - 10/2004
4	Uveal melanoma 11/2008 - 02/2006
3	Neoplasm Metastasis (Metastasis) 01/2022 - 02/2006
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2022
1	Bullous Pemphigoid (Pemphigoid) 11/2020
1	Hutchinson's Melanotic Freckle (Lentigo Maligna) 10/2020
1	Carcinoma (Carcinomatosis) 09/2018
1	Pathologic Processes 01/2018
1	Hyperhidrosis 01/2015
1	Ewing Sarcoma (Sarcoma, Ewing) 12/2012
1	Glioblastoma (Glioblastoma Multiforme) 01/2010
1	Synovial Sarcoma (Synovioma) 04/2008
1	Craniopharyngioma (Craniopharyngiomas) 07/2005

Drug/Important Bio-Agent (IBA)

9	Insulin-Like PeptidesIBA 10/2019 - 07/2003
8	Insulin (Novolin)FDA Link 01/2021 - 01/2004
5	picropodophyllinIBA 01/2010 - 02/2006
3	Pharmaceutical PreparationsIBA 01/2022 - 01/2015
3	Small Interfering RNA (siRNA)IBA 01/2022 - 04/2007
3	Phosphotransferases (Kinase)IBA 01/2021 - 07/2013
3	tyrosine receptor (receptor, tyrosine)IBA 01/2021 - 07/2013
3	IGF Type 1 Receptor (IGF 1 Receptor)IBA 11/2008 - 07/2005
2	Biological ProductsIBA 01/2021 - 01/2018
2	ArrestinIBA 01/2021 - 12/2012
2	Matrix Metalloproteinase 2 (Gelatinase A)IBA 11/2008 - 02/2006
2	Extracellular Matrix ProteinsIBA 11/2008 - 02/2006
2	Cisplatin (Platino)FDA LinkGeneric 11/2008 - 06/2008
2	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2008 - 06/2008
2	Imatinib Mesylate (Gleevec)FDA Link 11/2008 - 06/2008
2	Fluorouracil (Carac)FDA LinkGeneric 11/2008 - 06/2008
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2008 - 06/2008
1	CarcinogensIBA 01/2022
1	nutlin 3IBA 01/2022
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2022
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2021
1	AgarIBA 09/2018
1	Proteins (Proteins, Gene)FDA Link 09/2018
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2017
1	LigandsIBA 02/2015
1	Aluminum ChlorideIBA 01/2015
1	Botulinum Toxins (Botulinum Toxin)IBA 01/2015
1	Cholinergic Antagonists (Anticholinergics)IBA 01/2015
1	AntibodiesIBA 12/2012
1	Antineoplastic Agents (Antineoplastics)IBA 06/2008
1	Cyclin D1IBA 04/2008
1	Insulin-Like Growth Factor I (IGF-1)IBA 07/2005
1	Growth Hormone (Somatotropin)IBA 07/2005
1	beta-ArrestinsIBA 07/2005
1	Protein Isoforms (Isoforms)IBA 07/2005
1	Phenylalanine (L-Phenylalanine)FDA Link 10/2004
1	Tyrosine (L-Tyrosine)FDA Link 10/2004
1	Mitogen-Activated Protein Kinase 3IBA 01/2004
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 07/2003

Therapy/Procedure

8	Therapeutics 01/2022 - 12/2012
2	Drug Therapy (Chemotherapy) 11/2008 - 02/2006
1	Mohs Surgery (Mohs' Micrographic Surgery) 01/2022
1	Immunotherapy 11/2021
1	Radiotherapy 10/2020
1	Precision Medicine 01/2018
1	Heterologous Transplantation (Xenotransplantation) 06/2008